Summary of interview
Professor Lutgens explains how her research career started as a medical student, when she became interested in the cardiovascular system and then the immune system. After spending a medical internship with Prof Mat Daemen at the University of Maastricht where she started looking at cellular proliferation in the atherosclerotic plaque, she discovered that there were important roles for immune cells in the plaque.
She has two key discoveries to date; she found expression of the CD40 ligand in the atherosclerotic plaque and followed this up with murine studies through a collaboration with the company Biogen and Richard Flavel at Yale University. They observed a striking phenotype in CD40 ligand deficient mice; they had reduced atherosclerosis and had stable plaques which are highly significant in the clinical setting. This led to further studies to elucidate the mechanism behind this signalling pathway and the discovery of the role of the intermediate signalling factor TRAF6 and its interaction with CD40 ligand. This interaction was found to be a key driver of atherosclerosis and led to the development of small molecule compounds to inhibit atherosclerosis progression. Professor Lutgens believes the next generation of therapies to target the immune system and atherosclerosis will be to combine lipid lowering drugs with immune modulators and to tailor those towards patients that respond differently.
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